|
Johnson & Johnson (JNJ) today announced sales of $17.1 billion for the third quarter of 2012, an increase of 6.5% as compared to the third quarter of 2011. Operational results increased 10.8% and the negative impact of currency was 4.3%. Domestic sales increased 13.4%. International sales increased 1.4%, reflecting operational growth of 8.9% and a negative currency impact of 7.5%. Sales included the impact of the recently completed acquisition of Synthes, Inc., which contributed 5.8% to worldwide operational sales growth, net of the divestiture of the DePuy trauma business.
Net earnings** and diluted earnings per share for the third quarter of 2012 were $3.0 billion and $1.05, respectively. Third-quarter 2012 net earnings included after-tax special items of $553 million, primarily consisting of a non-cash net charge related to in-process research and development due to the discontinuation of the phase 3 clinical development of bapineuzumab IV, transaction and integration costs related to the acquisition of Synthes, Inc., and DePuy ASR(TM) Hip related costs. Third-quarter 2011 net earnings included an after-tax special item of $241 million, consisting of a mark-to-market adjustment to the value of the currency option and deal costs related to the acquisition of Synthes, Inc. Excluding these special items, net earnings for the current quarter were $3.5 billion and diluted earnings per share were $1.25, representing increases of 2.3% and 0.8%, respectively, as compared to the same period in 2011.*
"Our third-quarter results reflected continued sales momentum driven by strong growth of key products, successful new product launches, and the addition of Synthes to our family of companies. We advanced our pipelines with regulatory approvals for a number of new products, the submission of several new drug applications, and the completion of several strategic collaborations," said Alex Gorsky, Chief Executive Officer. "I’m extremely proud of our talented and dedicated colleagues throughout Johnson & Johnson and I have great confidence in our ability to deliver sustainable growth and bring meaningful innovations to patients and customers around the world."
The Company updated its earnings guidance for full-year 2012 to $5.05 - $5.10 per share. The Company’s guidance excludes the impact of special items.
Worldwide Consumer sales of $3.6 billion for the third quarter represented a decrease of 4.3% versus the prior year consisting of an operational increase of 1.0% and a negative impact from currency of 5.3%. Domestic sales decreased 0.4%. International sales decreased 6.1%, which reflected an operational increase of 1.8% and a negative currency impact of 7.9%.
Positive contributors to operational results were sales of upper respiratory over-the-counter products; international sales of LISTERINE? oral care products; and NEUTROGENA? skin care products.
Worldwide Pharmaceutical sales of $6.4 billion for the third quarter represented an increase of 7.0% versus the prior year with operational growth of 11.3% and a negative impact from currency of 4.3%. Domestic sales increased 14.6%. International sales were flat and reflected an operational increase of 8.2% offset by a negative currency impact of 8.2%.
Primary contributors to operational sales growth were REMICADE? (infliximab), a biologic approved for the treatment of a number of immune-mediated, inflammatory diseases; PREZISTA? (darunavir), a treatment for HIV; VELCADE? (bortezomib), a treatment for multiple myeloma; and a number of recently launched products.
The strong sales results of recently launched products included ZYTIGA? (abiraterone acetate), an oral, once-daily medication for use in combination with prednisone, for the treatment of metastatic, castration-resistant prostate cancer; INVEGA? SUSTENNA?/XEPLION? (paliperidone palmitate), a once-monthly, long-acting, injectable atypical antipsychotic for the acute and maintenance treatment of schizophrenia in adults; STELARA? (ustekinumab), a biologic approved for the treatment of moderate to severe plaque psoriasis; international sales of INCIVO? (telaprevir), a direct acting antiviral protease inhibitor, for the treatment of genotype-1 chronic hepatitis C virus, in combination with peginterferon alfa and ribavirin, in adults; XARELTO? (rivaroxaban), an oral anticoagulant; and SIMPONI? (golimumab), a biologic approved to treat adults with moderate to severe rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
Sales results were negatively impacted by the manufacturing suspension at a third-party supplier for DOXIL? (doxorubicin HCl liposome injection)/CAELYX? (pegylated liposomal doxorubicin hydrochloride), a medication to treat ovarian and other cancers.
During the quarter, the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application for NUCYNTA? ER (tapentadol) extended-release tablets, an oral analgesic taken twice daily, for the management of neuropathic pain associated with diabetic peripheral neuropathy in adults. In addition, the European Commission approved the marketing authorizations for DACOGEN? (decitabine) for the treatment of adult patients (age 65 years and above) with newly diagnosed de novo or secondary acute myeloid leukemia who are not candidates for standard induction chemotherapy, and for the subcutaneous administration of VELCADE? (bortezomib) for the treatment of multiple myeloma.
Also during the quarter, a Biologics License Application was submitted to the FDA requesting approval of an investigational intravenous formulation of the anti-tumor necrosis factor (TNF)-alpha SIMPONI? (golimumab) for the treatment of adults with moderately to severely active rheumatoid arthritis. In addition, a supplemental Biologics License Application was submitted to the FDA and a Type II Variation was submitted to the European Medicines Agency (EMA) requesting approval of SIMPONI? (golimumab) for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy.
In August, a Marketing Authorization Application was submitted to the EMA seeking conditional approval for the use of bedaquiline (TMC207) as an oral treatment, to be used as part of combination therapy for pulmonary, multi-drug resistant tuberculosis in adults.
In October, a license agreement was entered into with Astellas Pharma Inc. for the worldwide development and commercialization, except in Japan, of ASP015K, an oral, small molecule Janus Kinase inhibitor. ASP015K is currently in Phase 2b development as a once-daily oral treatment for moderate-to-severe rheumatoid arthritis.
Worldwide Medical Devices and Diagnostics sales of $7.1 billion for the third quarter represented an increase of 12.5% versus the prior year consisting of an operational increase of 16.1% and a negative currency impact of 3.6%. Domestic sales increased 18.3%. International sales increased 7.9%, which reflected an operational increase of 14.4% and a negative currency impact of 6.5%. Sales included the impact of the recently completed acquisition of Synthes, Inc., which contributed 14.7%, 17.9%, and 12.2% to worldwide, domestic and international operational sales growth, respectively, net of the divestiture of the DePuy trauma business.
Primary contributors to operational growth were sales from the recently completed acquisition of Synthes, Inc. in our Orthopaedics business; Biosense Webster’s electrophysiology products in our Cardiovascular Care business; a number of products in our Specialty Surgery business; and Vistakon’s disposable contact lenses.
During the quarter, Calibra Medical, Inc., a privately held developer of a unique, wearable three-day insulin patch designed to offer a convenient and discrete mealtime insulin dosing option for people with diabetes who take multiple daily injections of insulin, was acquired.
About Johnson & Johnson Caring for the world, one person at a time...inspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 129,000 employees at more than 250 Johnson & Johnson operating companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.
* Net earnings** and diluted earnings per share excluding special items are non-GAAP financial measures and should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP financial measures is included in the financial schedules accompanying this press release and can be found in the Investor Relations section of the Company’s website at www.investor.jnj.com.
** Net earnings attributable to Johnson & Johnson.
NOTE TO INVESTORS
Johnson & Johnson will conduct a conference call with financial analysts to discuss this news release today at 8:30 a.m., Eastern Time. A simultaneous webcast of the meeting for investors and other interested parties may be accessed by visiting the Johnson & Johnson website at www.investor.jnj.com. A replay and podcast will be available approximately two hours after the live webcast by visiting www.investor.jnj.com.
Copies of the financial schedules accompanying this press release are available at www.investor.jnj.com/historical-sales.cfm. These schedules include supplementary sales data, condensed consolidated statements of earnings, and sales of key products/franchises. Additional information on Johnson & Johnson, including a pharmaceutical pipeline of selected compounds in late stage development and medical devices and diagnostics pipeline of selected products, can be found on the Company’s website at www.jnj.com
(This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to, general industry conditions and competition; economic factors, such as interest rate and currency exchange rate fluctuations; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; challenges to patents; significant adverse litigation or government action; impact of business combinations; financial distress and bankruptcies experienced by significant customers and suppliers; changes to governmental laws and regulations and domestic and foreign health care reforms; trends toward health care cost containment; increased scrutiny of the health care industry by government agencies; changes in behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and sovereign risk; disruptions due to natural disasters; manufacturing difficulties or delays; and product efficacy or safety concerns resulting in product recalls or regulatory action. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended January 1, 2012. Copies of this Form 10-K, as well as subsequent filings, are available online at www.sec.gov, www.investor.jnj.com or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statements as a result of new information or future events or developments.)
Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions) THIRD QUARTER NINE MONTHS
Percent Change Percent Change
2012 2011 Total Operations Currency 2012 2011 Total Operations Currency
Sales to customers by
segment of business
Consumer
U.S. $ 1,214 1,219 (0.4) % (0.4) - $ 3,843 3,903 (1.5) % (1.5) -
International 2,367 2,521 (6.1) 1.8 (7.9) 6,952 7,312 (4.9) 1.4 (6.3)
3,581 3,740 (4.3) 1.0 (5.3) 10,795 11,215 (3.7) 0.4 (4.1)
Pharmaceutical
U.S. 3,288 2,869 14.6 14.6 - 9,408 9,499 (1.0) (1.0) -
International 3,114 3,113 0.0 8.2 (8.2) 9,418 8,775 7.3 14.1 (6.8)
6,402 5,982 7.0 11.3 (4.3) 18,826 18,274 3.0 6.3 (3.3)
Med Devices & Diagnostics
U.S. 3,289 2,780 18.3 18.3 - 9,119 8,521 7.0 7.0 -
International 3,780 3,503 7.9 14.4 (6.5) 10,926 10,765 1.5 6.2 (4.7)
7,069 6,283 12.5 16.1 (3.6) 20,045 19,286 3.9 6.5 (2.6)
U.S. 7,791 6,868 13.4 13.4 - 22,370 21,923 2.0 2.0 -
International 9,261 9,137 1.4 8.9 (7.5) 27,296 26,852 1.7 7.5 (5.8)
Worldwide $ 17,052 16,005 6.5 % 10.8 (4.3) $ 49,666 48,775 1.8 % 5.0 (3.2)
Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions) THIRD QUARTER NINE MONTHS
Percent Change Percent Change
2012 2011 Total Operations Currency 2012 2011 Total Operations Currency
Sales to customers by
geographic area
U.S. $ 7,791 6,868 13.4 % 13.4 - $ 22,370 21,923 2.0 % 2.0 -
Europe 3,983 4,124 (3.4) 7.1 (10.5) 12,342 12,850 (4.0) 4.2 (8.2)
Western Hemisphere excluding U.S. 1,824 1,751 4.2 12.8 (8.6) 5,266 4,730 11.3 19.1 (7.8)
Asia-Pacific, Africa 3,454 3,262 5.9 9.0 (3.1) 9,688 9,272 4.5 6.1 (1.6)
International 9,261 9,137 1.4 8.9 (7.5) 27,296 26,852 1.7 7.5 (5.8)
Worldwide $ 17,052 16,005 6.5 % 10.8 (4.3) $ 49,666 48,775 1.8 % 5.0 (3.2)
Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings
(Unaudited; in Millions Except Per Share Figures) THIRD QUARTER
2012 2011 Percent
Percent Percent Increase
Amount to Sales Amount to Sales (Decrease)
Sales to customers $ 17,052 100.0 $ 16,005 100.0 6.5
Cost of products sold 5,597 32.8 5,072 31.7 10.4
Selling, marketing and administrative expenses 5,228 30.6 5,240 32.7 (0.2)
Research and development expense 1,923 11.3 1,773 11.1 8.5
In-process research and development 679 4.0 - -
Interest (income) expense, net 120 0.7 117 0.7
Other (income) expense, net (90) (0.5) (308) (1.9)
Earnings before provision for taxes on income 3,595 21.1 4,111 25.7 (12.6)
Provision for taxes on income 966 5.7 909 5.7 6.3
Net earnings 2,629 15.4 3,202 20.0 (17.9)
Add: Net loss attributable to noncontrolling interest 339 2.0 - -
Net earnings attributable to Johnson & Johnson $ 2,968 17.4 $ 3,202 20.0 (7.3)
Net earnings per share attributable to Johnson & Johnson (Diluted) $ 1.05 $ 1.15 (8.7)
Average shares outstanding (Diluted) 2,818.1 2,778.2
Effective tax rate 26.9 % 22.1 %
Adjusted earnings before provision for taxes and net earnings
attributable to Johnson & Johnson (1)
Earnings before provision for taxes on income $ 4,525 26.5 $ 4,427 27.7 2.2
Net earnings attributable to Johnson & Johnson $ 3,521 20.6 $ 3,443 21.5 2.3
Net earnings per share attributable to Johnson & $ 1.25 $ 1.24 0.8
Johnson (Diluted)
Effective tax rate 22.2 % 22.2 %
(1) See Reconciliation of Non-GAAP Financial Measures.
Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings
(Unaudited; in Millions Except Per Share Figures) NINE MONTHS
2012 2011 Percent
Percent Percent Increase
Amount to Sales Amount to Sales (Decrease)
Sales to customers $ 49,666 100.0 $ 48,775 100.0 1.8
Cost of products sold 15,655 31.5 15,022 30.8 4.2
Selling, marketing and administrative expenses 15,208 30.6 15,511 31.8 (2.0)
Research and development expense 5,334 10.7 5,393 11.0 (1.1)
In-process research and development 1,108 2.2 - -
Interest (income) expense, net 379 0.8 332 0.7
Other (income) expense, net 1,307 2.7 (115) (0.2)
Restructuring expense - - 589 1.2
Earnings before provision for taxes on income 10,675 21.5 12,043 24.7 (11.4)
Provision for taxes on income 2,728 5.5 2,589 5.3 5.4
Net earnings 7,947 16.0 9,454 19.4 (15.9)
Add: Net loss attributable to noncontrolling interest 339 0.7 - -
Net earnings attributable to Johnson & Johnson $ 8,286 16.7 $ 9,454 19.4 (12.4)
Net earnings per share attributable to Johnson & Johnson (Diluted) $ 2.96 $ 3.40 (12.9)
Average shares outstanding (Diluted) 2,805.0 2,777.6
Effective tax rate 25.6 % 21.5 %
Adjusted earnings before provision for taxes and net earnings
attributable to Johnson & Johnson (1)
Earnings before provision for taxes on income $ 14,099 28.4 $ 13,696 28.1 2.9
Net earnings attributable to Johnson & Johnson $ 10,969 22.1 $ 10,738 22.0 2.2
Net earnings per share attributable to Johnson & Johnson $ 3.91 $ 3.87 1.0
(Diluted)
Effective tax rate 22.2 % 21.6 %
(1) See Reconciliation of Non-GAAP Financial Measures.
Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
Third Quarter % Incr. / Nine Months YTD % Incr. /
(Dollars in Millions Except Per Share Data) 2012 2011 (Decr.) 2012 2011 (Decr.)
Earnings before provision for taxes on income - as reported $ 3,595 4,111 (12.6) % $ 10,675 $ 12,043 (11.4) %
Intangible asset write-downs/adjustments (30) - 909 -
Net litigation - - 669 576
Synthes integration/transaction costs and currency related 165 (1) 316 622 214
In-process research and development 679 - 1,108 -
Restructuring - Cordis - - - 676
DePuy ASR(TM)Hip related costs 116 - 116 187
Earnings before provision for taxes on income - as adjusted $ 4,525 4,427 2.2 % $ 14,099 13,696 2.9 %
Net Earnings attributable to Johnson & Johnson - as reported $ 2,968 3,202 (7.3) % $ 8,286 9,454 (12.4) %
Intangible asset write-downs (16) - 701 -
Net litigation - - 611 444
Synthes integration/transaction costs and currency related 135 241 593 139
In-process research and development 340 (2) - 684 -
Restructuring - Cordis - - - 549
DePuy ASR(TM)Hip related costs 94 - 94 152
Net Earnings attributable to Johnson & Johnson - as adjusted $ 3,521 3,443 2.3 % $ 10,969 10,738 2.2 %
Diluted Net Earnings per share attributable to Johnson & Johnson - as reported $ 1.05 1.15 (8.7) % $ 2.96 3.40 (12.9) %
Intangible asset write-downs (0.01) - 0.25 -
Net litigation - - 0.22 0.16
Synthes integration/transaction costs and currency related 0.05 0.09 0.21 0.05
In-process research and development 0.13 - 0.24 -
Restructuring - Cordis - - - 0.20
DePuy ASR(TM)Hip related costs 0.03 - 0.03 0.06
Diluted Net Earnings per share attributable to Johnson & Johnson - as adjusted $ 1.25 1.24 0.8 % $ 3.91 3.87 1.0 %
(1) Represents inventory step-up recorded in cost of products sold
(2) In-process research and development of $679M offset by $339M reported as net loss attributable to noncontrolling interest
The Company believes investors gain additional perspective of underlying business trends and results by providing a measure of earnings before provision for taxes on income, net earnings and diluted net earnings per share that excludes special items in order to evaluate ongoing business operations.
REPORTED SALES vs. PRIOR PERIOD ($MM)
THIRD QUARTER NINE MONTHS
% Change % Change
2012 2011 Reported Operational (1) Currency 2012 2011 Reported Operational (1) Currency
CONSUMER SEGMENT (2)
BABY CARE
US $ 104 105 -1.0% -1.0% - $ 309 315 -1.9% -1.9% -
Intl 460 508 -9.4% -2.1% -7.3% 1,373 1,457 -5.8% 0.3% -6.1%
WW 564 613 -8.0% -1.9% -6.1% 1,682 1,772 -5.1% -0.1% -5.0%
ORAL CARE
US 162 162 0.0% 0.0% - 476 483 -1.4% -1.4% -
Intl 251 260 -3.5% 4.7% -8.2% 732 729 0.4% 7.1% -6.7%
WW 413 422 -2.1% 3.0% -5.1% 1,208 1,212 -0.3% 3.7% -4.0%
OTC/NUTRITIONALS
US 351 332 5.7% 5.7% - 1,068 1,059 0.8% 0.8% -
Intl 709 722 -1.8% 6.0% -7.8% 2,128 2,207 -3.6% 2.5% -6.1%
WW 1,060 1,054 0.6% 5.9% -5.3% 3,196 3,266 -2.1% 2.0% -4.1%
SKIN CARE
US 390 376 3.7% 3.7% - 1,314 1,251 5.0% 5.0% -
Intl 514 567 -9.3% -2.2% -7.1% 1,410 1,520 -7.2% -1.4% -5.8%
WW 904 943 -4.1% 0.2% -4.3% 2,724 2,771 -1.7% 1.5% -3.2%
WOMEN’S HEALTH
US 81 104 -22.1% -22.1% - 254 350 -27.4% -27.4% -
Intl 326 354 -7.9% 2.3% -10.2% 964 1,044 -7.7% 0.2% -7.9%
WW 407 458 -11.1% -3.2% -7.9% 1,218 1,394 -12.6% -6.7% -5.9%
WOUND CARE/OTHER
US 126 140 -10.0% -10.0% - 422 445 -5.2% -5.2% -
Intl 107 110 -2.7% 4.5% -7.2% 345 355 -2.8% 3.0% -5.8%
WW 233 250 -6.8% -3.6% -3.2% 767 800 -4.1% -1.5% -2.6%
TOTAL CONSUMER
US 1,214 1,219 -0.4% -0.4% - 3,843 3,903 -1.5% -1.5% -
Intl 2,367 2,521 -6.1% 1.8% -7.9% 6,952 7,312 -4.9% 1.4% -6.3%
WW $ 3,581 3,740 -4.3% 1.0% -5.3% $ 10,795 11,215 -3.7% 0.4% -4.1%
See footnotes at end of schedule
REPORTED SALES vs. PRIOR PERIOD ($MM)
THIRD QUARTER NINE MONTHS
% Change % Change
2012 2011 Reported Operational (1) Currency 2012 2011 Reported Operational (1) Currency
PHARMACEUTICAL SEGMENT (2) (4)
IMMUNOLOGY
US $ 1,600 1,390 15.1% 15.1% - $ 4,524 4,350 4.0% 4.0% -
Intl 484 377 28.4% 37.1% -8.7% 1,374 652 * * -5.7%
WW 2,084 1,767 17.9% 19.8% -1.9% 5,898 5,002 17.9% 19.2% -1.3%
REMICADE
US 940 876 7.3% 7.3% - 2,712 2,500 8.5% 8.5% -
US Exports (3) 379 343 10.5% 10.5% - 1,123 1,360 -17.4% -17.4% -
Intl 272 189 43.9% 53.2% -9.3% 800 204 * * -5.7%
WW 1,591 1,408 13.0% 14.3% -1.3% 4,635 4,064 14.1% 15.1% -1.0%
SIMPONI
US 93 59 57.6% 57.6% - 220 173 27.2% 27.2% -
Intl 92 70 31.4% 39.7% -8.3% 206 118 74.6% 83.0% -8.4%
WW 185 129 43.4% 47.9% -4.5% 426 291 46.4% 49.8% -3.4%
STELARA
US 188 112 67.9% 67.9% - 469 317 47.9% 47.9% -
Intl 99 77 28.6% 39.5% -10.9% 287 214 34.1% 43.3% -9.2%
WW 287 189 51.9% 56.4% -4.5% 756 531 42.4% 46.1% -3.7%
OTHER IMMUNOLOGY
US - - - - - - - - - -
Intl 21 41 -48.8% -46.6% -2.2% 81 116 -30.2% -27.2% -3.0%
WW 21 41 -48.8% -46.6% -2.2% 81 116 -30.2% -27.2% -3.0%
INFECTIOUS DISEASES
US 259 216 19.9% 19.9% - 738 1,191 -38.0% -38.0% -
Intl 536 498 7.6% 18.0% -10.4% 1,600 1,282 24.8% 34.1% -9.3%
WW 795 714 11.3% 18.6% -7.3% 2,338 2,473 -5.5% -0.7% -4.8%
INTELENCE
US 45 42 7.1% 7.1% - 130 118 10.2% 10.2% -
Intl 49 41 19.5% 32.1% -12.6% 135 113 19.5% 29.2% -9.7%
WW 94 83 13.3% 19.5% -6.2% 265 231 14.7% 19.4% -4.7%
LEVAQUIN/FLOXIN
US 10 14 -28.6% -28.6% - 35 585 -94.0% -94.0% -
Intl 10 11 -9.1% -4.8% -4.3% 30 33 -9.1% -4.2% -4.9%
WW 20 25 -20.0% -18.1% -1.9% 65 618 -89.5% -89.2% -0.3%
PREZISTA
US 181 132 37.1% 37.1% - 507 386 31.3% 31.3% -
Intl 183 184 -0.5% 9.9% -10.4% 554 509 8.8% 17.7% -8.9%
WW 364 316 15.2% 21.3% -6.1% 1,061 895 18.5% 23.5% -5.0%
OTHER INFECTIOUS DISEASES
US 23 28 -17.9% -17.9% - 66 102 -35.3% -35.3% -
Intl 294 262 12.2% 22.6% -10.4% 881 627 40.5% 50.4% -9.9%
WW 317 290 9.3% 18.7% -9.4% 947 729 29.9% 38.4% -8.5%
REPORTED SALES vs. PRIOR PERIOD ($MM)
THIRD QUARTER NINE MONTHS
% Change % Change
2012 2011 Reported Operational (1) Currency 2012 2011 Reported Operational (1) Currency
NEUROSCIENCE
US 678 634 6.9% 6.9% - 2,010 2,006 0.2% 0.2% -
Intl 990 1,050 -5.7% 1.2% -6.9% 3,019 3,203 -5.7% -0.4% -5.3%
WW 1,668 1,684 -1.0% 3.3% -4.3% 5,029 5,209 -3.5% -0.2% -3.3%
CONCERTA/METHYLPHENIDATE
US 150 179 -16.2% -16.2% - 493 667 -26.1% -26.1% -
Intl 104 104 0.0% 6.8% -6.8% 337 327 3.1% 9.1% -6.0%
WW 254 283 -10.2% -7.7% -2.5% 830 994 -16.5% -14.5% -2.0%
INVEGA
US 78 74 5.4% 5.4% - 223 219 1.8% 1.8% -
Intl 62 52 19.2% 26.9% -7.7% 180 155 16.1% 21.5% -5.4%
WW 140 126 11.1% 14.3% -3.2% 403 374 7.8% 10.0% -2.2%
INVEGA SUSTENNA/ XEPLION
US 130 85 52.9% 52.9% - 350 220 59.1% 59.1% -
Intl 82 16 * * -8.7% 218 23 * * -7.1%
WW 212 101 * * -3.4% 568 243 * * -2.7%
RISPERDAL CONSTA
US 113 111 1.8% 1.8% - 336 335 0.3% 0.3% -
Intl 238 279 -14.7% -7.2% -7.5% 731 863 -15.3% -9.4% -5.9%
WW 351 390 -10.0% -4.6% -5.4% 1,067 1,198 -10.9% -6.7% -4.2%
OTHER NEUROSCIENCE
US 207 185 11.9% 11.9% - 608 565 7.6% 7.6% -
Intl 504 599 -15.9% -10.3% -5.6% 1,553 1,835 -15.4% -11.3% -4.1%
WW 711 784 -9.3% -5.0% -4.3% 2,161 2,400 -10.0% -6.9% -3.1%
ONCOLOGY
US 145 79 83.5% 83.5% - 371 236 57.2% 57.2% -
Intl 483 415 16.4% 27.3% -10.9% 1,439 1,249 15.2% 23.6% -8.4%
WW 628 494 27.1% 36.2% -9.1% 1,810 1,485 21.9% 29.0% -7.1%
DOXIL/CAELYX
US 9 10 -10.0% -10.0% - 22 130 -83.1% -83.1% -
Intl 7 76 -90.8% -89.6% -1.2% 31 233 -86.7% -85.4% -1.3%
WW 16 86 -81.4% -80.4% -1.0% 53 363 -85.4% -84.6% -0.8%
VELCADE
US - - - - - - - - - -
Intl 327 295 10.8% 20.7% -9.9% 998 922 8.2% 15.7% -7.5%
WW 327 295 10.8% 20.7% -9.9% 998 922 8.2% 15.7% -7.5%
ZYTIGA
US 136 69 97.1% 97.1% - 349 106 * * -
Intl 129 26 * * -10.7% 348 43 * * -8.5%
WW 265 95 * * -5.2% 697 149 * * -4.2%
OTHER ONCOLOGY
US - - - - - - - - - -
Intl 20 18 11.1% 18.8% -7.7% 62 51 21.6% 28.1% -6.5%
WW 20 18 11.1% 18.8% -7.7% 62 51 21.6% 28.1% -6.5%
REPORTED SALES vs. PRIOR PERIOD ($MM)
THIRD QUARTER NINE MONTHS
% Change % Change
2012 2011 Reported Operational (1) Currency 2012 2011 Reported Operational (1) Currency
TOTAL OTHER
US 606 550 10.2% 10.2% - 1,765 1,716 2.9% 2.9% -
Intl 621 773 -19.7% -12.8% -6.9% 1,986 2,389 -16.9% -11.6% -5.3%
WW 1,227 1,323 -7.3% -3.3% -4.0% 3,751 4,105 -8.6% -5.5% -3.1%
ACIPHEX/PARIET
US 80 94 -14.9% -14.9% - 280 304 -7.9% -7.9% -
Intl 115 141 -18.4% -9.2% -9.2% 369 417 -11.5% -4.1% -7.4%
WW 195 235 -17.0% -11.5% -5.5% 649 721 -10.0% -5.7% -4.3%
PROCRIT/EPREX
US 198 176 12.5% 12.5% - 634 623 1.8% 1.8% -
Intl 161 207 -22.2% -14.6% -7.6% 502 632 -20.6% -14.5% -6.1%
WW 359 383 -6.3% -2.2% -4.1% 1,136 1,255 -9.5% -6.4% -3.1%
OTHER
US 328 280 17.1% 17.1% - 851 789 7.9% 7.9% -
Intl 345 425 -18.8% -13.1% -5.7% 1,115 1,340 -16.8% -12.5% -4.3%
WW 673 705 -4.5% -1.1% -3.4% 1,966 2,129 -7.7% -5.0% -2.7%
TOTAL PHARMACEUTICAL
US 3,288 2,869 14.6% 14.6% - 9,408 9,499 -1.0% -1.0% -
Intl 3,114 3,113 0.0% 8.2% -8.2% 9,418 8,775 7.3% 14.1% -6.8%
WW $ 6,402 5,982 7.0% 11.3% -4.3% $ 18,826 18,274 3.0% 6.3% -3.3%
See footnotes at end of schedule
REPORTED SALES vs. PRIOR PERIOD ($MM)
THIRD QUARTER NINE MONTHS
% Change % Change
2012 2011 Reported Operational (1) Currency 2012 2011 Reported Operational (1) Currency
MEDICAL DEVICES AND DIAGNOSTICS (2)(4)
CARDIOVASCULAR CARE
US $ 195 198 -1.5% -1.5% - $ 566 650 -12.9% -12.9% -
Intl 298 328 -9.1% -3.3% -5.8% 913 1,098 -16.8% -13.0% -3.8%
WW 493 526 -6.3% -2.7% -3.6% 1,479 1,748 -15.4% -13.0% -2.4%
DIABETES CARE
US 328 338 -3.0% -3.0% - 1,017 982 3.6% 3.6% -
Intl 301 326 -7.7% 0.8% -8.5% 955 1,000 -4.5% 1.9% -6.4%
WW 629 664 -5.3% -1.1% -4.2% 1,972 1,982 -0.5% 2.8% -3.3%
DIAGNOSTICS
US 256 265 -3.4% -3.4% - 767 811 -5.4% -5.4% -
Intl 257 274 -6.2% -0.5% -5.7% 772 799 -3.4% 0.9% -4.3%
WW 513 539 -4.8% -1.9% -2.9% 1,539 1,610 -4.4% -2.3% -2.1%
INFECTION PREVENTION/OTHER
US 98 90 8.9% 8.9% - 313 283 10.6% 10.6% -
Intl 134 130 3.1% 9.0% -5.9% 393 385 2.1% 6.2% -4.1%
WW 232 220 5.5% 9.0% -3.5% 706 668 5.7% 8.1% -2.4%
ORTHOPAEDICS
US 1,242 737 68.5% 68.5% - 2,898 2,318 25.0% 25.0% -
Intl 1,048 647 62.0% 68.7% -6.7% 2,513 2,038 23.3% 28.3% -5.0%
WW 2,290 1,384 65.5% 68.6% -3.1% 5,411 4,356 24.2% 26.5% -2.3%
SPECIALTY SURGERY
US 308 292 5.5% 5.5% - 971 899 8.0% 8.0% -
Intl 289 284 1.8% 9.1% -7.3% 900 874 3.0% 8.7% -5.7%
WW 597 576 3.6% 7.2% -3.6% 1,871 1,773 5.5% 8.3% -2.8%
SURGICAL CARE (5)
US 602 609 -1.1% -1.1% - 1,797 1,826 -1.6% -1.6% -
Intl 949 1,013 -6.3% 0.9% -7.2% 3,019 3,117 -3.1% 2.2% -5.3%
WW 1,551 1,622 -4.4% 0.1% -4.5% 4,816 4,943 -2.6% 0.8% -3.4%
VISION CARE
US 260 251 3.6% 3.6% - 790 752 5.1% 5.1% -
Intl 504 501 0.6% 4.8% -4.2% 1,461 1,454 0.5% 2.9% -2.4%
WW 764 752 1.6% 4.4% -2.8% 2,251 2,206 2.0% 3.6% -1.6%
TOTAL MEDICAL DEVICES AND DIAGNOSTICS
US 3,289 2,780 18.3% 18.3% - 9,119 8,521 7.0% 7.0% -
Intl 3,780 3,503 7.9% 14.4% -6.5% 10,926 10,765 1.5% 6.2% -4.7%
WW $ 7,069 6,283 12.5% 16.1% -3.6% $ 20,045 19,286 3.9% 6.5% -2.6%
* Percentage greater than 100%
(1) Operational growth excludes the effect of currency
(2) Select areas (unaudited)
(3) Reported as U.S. sales
(4) Prior year amounts have been reclassified to conform to current year product disclosure
(5) Previously referred to as General Surgery
SOURCE Johnson & Johnson
|
